How-To Guide
How to Use AI for a Gastroenterology Practice in 2026: CADe/CADx Colonoscopy, ERCP, IBD & Practice Ops
Published May 20, 2026 · 17 min read · For gastroenterologist-owners of 1-5 MD GI practices — general GI, hepatology, IBD, motility, advanced endoscopy, ERCP/EUS.
TL;DR
- Two AI layers for a GI practice in 2026: a clinical layer (ambient SOAP, CADe/CADx colonoscopy, ERCP/EUS planning, IBD biologic PA, hepatology risk stratification) and an operations layer (colon-cancer screening recall, denial appeals, MIPS quality dashboard, owner scorecard).
- Ten prompts below: GI new-patient intake, ambient-scribed GI SOAP with endoscopy CPT, CADe/CADx colonoscopy workflow, ERCP/EUS planning brief, IBD biologic PA letter, hepatology NAFLD/NASH risk triage, colon-cancer screening recall, denial appeal drafter, owner monthly scorecard, HIPAA-safe review reply.
- AI drafts; the gastroenterologist signs. Every note carries a HIPAA 45 CFR 164 minimum-necessary duty, an ACG/AGA/ASGE clinical-guideline accountability, and a MIPS quality-measure exposure — AI does not absorb any of them.
- PHI goes only into BAA-covered or enterprise-tenanted AI. ABA-equivalent medical-board AI guidance (FSMB Model Policy, CA AB 3030, TX SB 815, UT HB 452, IL HB 1806, NY S1331A pending) requires verbal patient consent before ambient scribing and written policy for AI-generated decision support.
- ROI is real: ADR +8-14 pts with CADe, 45-90 min/day saved per clinician on documentation, same-day biologic PA turnaround — but only if you track on-rate, scribe adoption, and PA velocity weekly.
The 2026 GI practice AI stack
| Layer | Tool | Use |
|---|---|---|
| EHR + GI module | Epic GI + Haiku, athenaOne GI, Oracle Cerner, ModMed Gastroenterology, Nextech GI, gGastro, ProVation | Clinical + endoscopy reporting |
| Ambient scribe | DeepScribe, Abridge, Suki, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai | GI SOAP drafts |
| CADe / CADx colonoscopy | Medtronic GI Genius, Iterative Scopes SKOUT, Magentiq-Eye MAGENTIQ-COLO, Olympus Endo-AID CADe, Fujifilm CAD EYE, Pentax DISCOVERY, ENDOANGEL | Polyp detection + characterization |
| ERCP / EUS | Olympus SpyGlass DS, Boston Scientific SpyGlass, Fujifilm EG-740 UT, Pentax EG-3870UTK, Mauna Kea Cellvizio AI, AI-Biliary | Biliary + pancreatic imaging |
| Hepatology | FibroScan 630, SuperSonic Aixplorer, Histoindex, PathAI Liver, NovaSignal | NAFLD/NASH + fibrosis |
| Pathology AI | PathAI, Paige.AI, Proscia, Ibex Medical Analytics, Deep Bio | GI biopsy overread |
| Prior auth | CoverMyMeds, Glidian, Myndshft, Availity, Waystar, Change Healthcare | Biologic + imaging PA |
| Recall + RCM | Weave AI, Doctible, Solutionreach, RevenueWell, Klara, Phreesia AI, BirdEye, Podium | Screening recall + reviews |
| Quality + registry | GIQuIC, AGA Digestive Health Outcomes Registry, MIPS MVP Advancing GI Care | ADR + APC + MIPS |
10 copy-paste prompts for your GI practice
1. New-patient intake synthesis
You are a GI clinical intake assistant. From the attached patient-completed intake, prior records, PCP referral, labs, prior endoscopy reports, and imaging, produce a 1-page synthesis:
1. Chief complaint + duration + red-flag review (hematochezia, melena, weight loss, dysphagia, anemia, family hx of CRC < 60, jaundice)
2. Relevant GI history (prior scopes with dates + findings, prior hospitalizations, surgeries, IBD history)
3. Medication list — flag NSAIDs, PPI, anticoagulants (apixaban/rivaroxaban/warfarin/clopidogrel), GLP-1 agonists (per ASA 2024 GLP-1 perioperative guidance)
4. Relevant family hx — first-degree relative with CRC, IBD, celiac, pancreatic cancer, hereditary syndromes (Lynch, FAP, Peutz-Jeghers)
5. Likely diagnostic differential (top 3) + proposed initial workup
6. Pre-procedure risk (ASA class, cardiac, pulmonary, anticoagulation hold plan)
7. Patient questions to address in visit
Do NOT make diagnostic conclusions. The gastroenterologist reviews and signs.
2. Ambient-scribed GI SOAP with endoscopy CPT
You are an ambient GI scribe (BAA-covered). From the clinic or endoscopy-suite audio, draft a SOAP note:
S: CC, HPI with GI-specific ROS, relevant PMH/PSH, meds, allergies, family hx
O: Vitals, GI-focused exam (abdominal, rectal if performed), labs, imaging
A: Assessment with GI differential
P: Plan with specific CPT coding:
- Office visit 99202-99215
- Colonoscopy: 45378 diagnostic, 45380 with biopsy, 45385 snare polypectomy, 45388 ablation, 45390 EMR
- EGD: 43235 diagnostic, 43239 biopsy, 43248 dilation, 43270 ablation
- ERCP: 43260-43278
- EUS: 43237-43238, 43242
- Modifier -33 (screening), -PT (screening converted to diagnostic), -59, -XU
- ICD-10: K21 GERD, K50/K51 IBD, K57 diverticular, Z12.11 screening CRC, K74 cirrhosis, K76.0 NAFLD, K86 pancreatic
Flag for physician review: anticoagulation plan, sedation ASA class, consent elements, bowel-prep adequacy (Boston Bowel Prep Scale).
Gastroenterologist reviews and signs before note finalization.
3. CADe/CADx colonoscopy workflow brief
You are a GI quality assistant. From the endoscopy report + CADe overlay output + pathology, produce a post-procedure quality brief:
1. Indication (screening 45378-33 vs diagnostic vs surveillance) + Boston Bowel Prep Scale segment scores
2. CADe tool used (GI Genius / SKOUT / MAGENTIQ-COLO / Endo-AID / CAD EYE / DISCOVERY / ENDOANGEL) + firmware version + FDA 510(k) reference
3. Polyps detected: count, size, Paris classification, location, resection method (cold snare, hot snare, EMR, ESD), retrieval confirmed
4. ADR contribution: flag if this procedure lifted or lowered endoscopist's rolling 90-day ADR
5. Withdrawal time ≥ 6 min per ASGE standard
6. Follow-up interval per USMSTF 2020 polyp surveillance guideline (1, 3, 5, 7-10 year)
7. Pathology reconciliation — flag any CADx optical-biopsy prediction that disagreed with pathology
Do NOT make billing decisions without physician sign-off. GIQuIC/MIPS export on completion.
4. ERCP / EUS planning brief
You are an advanced-endoscopy planning assistant. From the MRCP/CT/US imaging, labs, and clinical question, produce an ERCP or EUS plan:
1. Indication classification (ASGE ERCP Quality Indicators — grade 1 high-benefit, grade 2, grade 3)
2. Pre-procedure risk (PEP risk factors per ESGE — female, young, prior PEP, SOD, difficult cannulation expected) + prophylaxis (rectal indomethacin 100 mg, wire-guided cannulation, PD stent if high-risk)
3. Planned maneuvers (biliary vs pancreatic cannulation, stone extraction, stent placement self-expandable metal vs plastic, sphincterotomy, cholangioscopy SpyGlass, pancreatoscopy)
4. EUS planning — linear vs radial, FNA vs FNB 19G/22G/25G, ROSE availability, suspected lesion classification (pancreatic mass, IPMN Fukuoka criteria, subepithelial lesion)
5. Anesthesia plan — MAC vs general, aspiration risk, GLP-1 hold per ASA
6. Consent elements — PEP, bleeding, perforation, cholangitis, sedation risk
7. Post-procedure monitoring + discharge criteria
Attending gastroenterologist reviews and signs.
5. IBD biologic prior-authorization letter
You are a PA drafter. Produce a biologic PA letter for [drug: Humira / Stelara / Skyrizi / Rinvoq / Entyvio / Zeposia / Tremfya / Omvoh / biosimilar] for [diagnosis: Crohn's disease / ulcerative colitis]:
1. Patient demographics + insurance + policy number
2. Diagnosis with ICD-10 (K50.xx Crohn's, K51.xx UC) + endoscopic confirmation date + Mayo/SES-CD/UCEIS severity score
3. Failed conventional therapy — list each with dose, duration, response, intolerance/contraindication (5-ASA, corticosteroids with dose + taper, immunomodulators azathioprine/6-MP/methotrexate with dose + TPMT status)
4. Prior biologic failure if any (primary non-response, secondary loss of response with trough + anti-drug antibody levels from Prometheus / LabCorp / Quest)
5. Labs: CRP, fecal calprotectin, CBC, CMP, TB QuantiFERON-Gold, HBV panel, latent-TB screen
6. Vaccination status — pneumococcal, influenza, HBV, shingles (Shingrix before immunosuppression)
7. Citation to ACG Crohn's Disease Guideline 2018 or UC Guideline 2019 supporting requested agent
8. Plan-specific policy number citation + step-therapy satisfaction
9. If denied — plan-specific peer-to-peer request + appeal rights
Gastroenterologist reviews and signs. Truthful under False Claims Act.
6. Hepatology NAFLD / MASLD / MASH risk triage
You are a hepatology triage assistant. From the intake + labs + imaging, risk-stratify MASLD (formerly NAFLD) per AASLD 2023 Practice Guidance:
1. Cardiometabolic criteria — BMI, T2DM, dyslipidemia, HTN
2. FIB-4 score (age, AST, ALT, platelets) — < 1.3 low-risk, 1.3-2.67 indeterminate, > 2.67 high-risk
3. If indeterminate or high-risk: recommend non-invasive test ladder — VCTE FibroScan, MR elastography, ELF
4. Alternative etiology screen — HBV, HCV, AIH, hemochromatosis, Wilson, AATD, celiac
5. Alcohol use AUDIT-C
6. MASH-cirrhosis risk → hepatology referral + HCC surveillance Q6 month US ± AFP
7. Treatment eligibility — resmetirom (Rezdiffra) per FDA 2024 label for non-cirrhotic MASH F2-F3; GLP-1 / SGLT-2 / pioglitazone per guideline
8. Cardiovascular risk — ASCVD, statin eligibility
Gastroenterologist reviews and signs. Do NOT diagnose without confirmatory testing.
7. Colon-cancer screening recall campaign
You are a screening-recall assistant. From the patient panel + prior endoscopy dates + surveillance intervals, generate a HIPAA-safe recall outreach:
1. Segment by surveillance bucket — USMSTF 2020 10yr (normal screen), 5-7yr (low-risk adenoma), 3yr (high-risk), 1yr (advanced), family history modifier
2. 5-touch sequence — portal message + email + SMS + phone + mailer — per patient preference
3. Message copy — plain language, no PHI in subject, MyChart / portal link
4. Alternatives tier — FIT annually, Cologuard every 3 years, CT colonography every 5 years (USMSTF + USPSTF Grade A/B 45-75)
5. TCPA compliance — quiet hours 8am-9pm local, prior express consent, opt-out honored
6. State mini-TCPA — CA, FL, MA, WA, PA, IL, MT, NH, CT, MD
7. Outcome tracking — book rate, no-show rate, FIT return rate, Cologuard positivity
8. Quality measure contribution — MIPS quality ID 113 CRC screening, MVP Advancing GI
Do NOT share PHI in SMS bodies. Gastroenterologist reviews messaging before send.
8. Denial appeal drafter for colonoscopy / EGD / EUS / biologic
You are an appeal drafter. From the denial letter + chart documentation, draft a Level 1 appeal:
1. Denial reason parsing — medical necessity, step-therapy, frequency, non-covered service, experimental/investigational
2. Policy citation — payer medical policy number + effective date + clinical criteria
3. Clinical justification — ACG/AGA/ASGE guideline citation + specific page + recommendation grade
4. Documentation attachments — pathology, prior endoscopy report, CT/MRI, labs, failed conservative therapy
5. Milliman MCG or InterQual criteria reference if applicable
6. Medicare NCD / MAC LCD reference for Medicare patients
7. Timeliness — calendar-day filing deadline per denial letter
8. Peer-to-peer request option + physician availability
9. State DOI escalation path for commercial denials
Gastroenterologist reviews and signs. Truthful under False Claims Act — no exaggeration of severity.
9. Owner monthly scorecard
You are a GI practice analyst. From the EHR + endoscopy + billing + MIPS data, produce a 1-page owner scorecard:
1. Procedure volume — screening colonoscopy, diagnostic colonoscopy, EGD, ERCP, EUS
2. Case-mix index + revenue per case
3. Quality dashboard — ADR by endoscopist (AGA benchmark ≥ 30% mixed, ≥ 25% female, ≥ 35% male), APC, withdrawal time ≥ 6 min, cecal intubation rate ≥ 95%, adequate prep rate ≥ 90%
4. PA velocity — median days to biologic approval + denial rate by payer
5. Complication metrics — post-polypectomy bleed, perforation, PEP (per ASGE standards)
6. Collection rate by payer + AR aging (current, 30-60, 60-90, > 90 days)
7. No-show rate + screening-recall conversion
8. MIPS MVP Advancing GI dashboard — composite score trend
9. Staffing + OR utilization + block time
10. Top 3 actions for next month with owner
Gastroenterologist + administrator reviews.
10. HIPAA-safe review reply template
You are a HIPAA-safe review-reply assistant. From the public review text, draft a reply:
1. Never confirm or deny the reviewer is a patient — HIPAA 45 CFR 164 breach if you do
2. Thank the reviewer for feedback
3. Offer a private channel — practice email, phone — for any clinical concern
4. If the review makes a factual inaccuracy about general practice policy (hours, insurance accepted), correct only the non-PHI fact
5. Keep to 2-3 sentences, warm tone
6. For 5-star: thank + invite back for next screening
7. For 1-3 star: empathize + offer offline resolution, no PHI, no defensive language
8. FTC Endorsement Guides 2023 compliance — no incentive for review removal, no fake reviews
Practice manager reviews before post.
Compliance floor — the guardrails the prompts assume
- HIPAA 45 CFR 160 + 164 — BAA required for every AI vendor touching PHI; minimum-necessary; §164.514 de-identification; §164.502(a)(5)(iii); HHS OCR enforcement.
- State AI-scribe + AI-use consent laws — CA AB 3030 effective January 2025; TX SB 815 effective September 2025; UT HB 452 AI Mental Health Policy Act; IL HB 1806 effective January 2026; NY S1331A pending; FSMB Model Policy on AI.
- FDA 510(k) SaMD — every CADe/CADx colonoscopy tool, Cellvizio AI, PathAI Liver, FibroScan 630 cleared under 510(k) with stated IFU; Predetermined Change Control Plan (PCCP) 2024 framework active; 21 CFR 803 MDR when device contributes to adverse outcome.
- ACG / AGA / ASGE clinical guidelines — ACG IBD, Crohn's, UC, IBS, H. pylori, celiac; AGA NAFLD/MASLD Practice Guidance; AASLD; ASGE ERCP Quality Indicators; USMSTF 2020 polyp surveillance; USPSTF CRC screening age 45-75 Grade A/B.
- CMS MIPS MVP Advancing GI Care — quality ID 113 CRC screening, ID 343 ADR, ID 185 colonoscopy follow-up; PI + IA components; VBP bundles.
- AKS / Stark + CMS Open Payments Sunshine Act — endoscopy-suite joint-venture structures, tower vendor consulting, ASC physician-ownership compliance; Ambulatory Surgical Center safe harbor.
- FTC Endorsement Guides 2023 + 2024-2025 + Fake Reviews Rule 16 CFR 465 — $51,744/violation FY 2026; state truth-in-advertising; state medical-board advertising rules.
- TCPA 47 U.S.C. §227 + state mini-TCPA — CA, FL, MA, WA, PA, IL, MT, NH, CT, MD; FCC 2024 one-to-one consent rule; quiet hours 8am-9pm local.
- False Claims Act + 21st Century Cures + Information Blocking 45 CFR 171 — truthful PA letters, information-blocking penalties $1M/violation, USCDI v4 interoperability.
60-day rollout plan
- Days 1-10: Sign BAAs with every AI vendor. Stand up an AI-use policy covering ambient scribing, CADe, PA, recall. Patient-consent verbiage in every intake.
- Days 11-20: Pilot ambient scribe with 2 clinicians in clinic, 1 in endoscopy. Baseline ADR per endoscopist over prior 90 days.
- Days 21-30: Activate CADe across all screening colonoscopies. Log tool version. Export to GIQuIC weekly.
- Days 31-40: Launch IBD biologic PA workflow + recall campaign. Track PA velocity + screening-recall conversion.
- Days 41-50: Denial-appeal drafter + scorecard wiring. MIPS MVP dashboard.
- Days 51-60: Owner review — ADR delta, scribe adoption %, PA median days, AR aging, no-show, net per-procedure. Keep what moves the number.
8 common mistakes
- Signing a scribe-drafted endoscopy note without reconciling the CPT to actual resection performed.
- Trusting CADx optical biopsy for resect-and-discard billing without pathology confirmation in jurisdictions that do not yet permit it.
- Sending PHI to consumer-tier AI (no BAA) — a HIPAA breach per §164.
- Skipping verbal patient consent for ambient scribing in states that require it (CA, TX, UT, IL).
- Reusing a PA letter template across patients without patient-specific clinical justification — False Claims Act exposure.
- Not logging CADe firmware version when ADR shifts — cannot demonstrate device-attribution to payers or auditors.
- Replying to a public review in a way that confirms a reviewer is a patient — HIPAA violation.
- Booking a colonoscopy without confirming GLP-1 hold per ASA perioperative guidance — aspiration-risk exposure.
FAQ
Does AI improve colonoscopy adenoma detection?
Yes — FDA-cleared CADe systems (Medtronic GI Genius, Iterative Scopes SKOUT, Magentiq-Eye MAGENTIQ-COLO, Olympus Endo-AID CADe, Fujifilm CAD EYE, Pentax DISCOVERY, ENDOANGEL) have demonstrated statistically significant adenoma detection rate (ADR) and adenomas-per-colonoscopy (APC) improvements in multiple randomized controlled trials and meta-analyses. The practical 2026 pattern: every screening colonoscopy uses a CADe overlay, the endoscopist still makes the resection-or-leave call, and ADR is tracked as a quality measure (MIPS quality ID 343, AGA benchmark >=30% for mixed-sex screening). CADx for optical-biopsy resect-and-discard is still evolving — check your state's billing rules and the AGA US Multi-Society Task Force position before billing a diagnostic decision without pathology.
Is AI safe for GI ambient scribing?
Yes, under BAA-covered enterprise deployment. DeepScribe, Abridge, Suki Assistant, Nuance DAX Copilot, Heidi, and Freed all sign BAAs and produce draft SOAP notes. For GI, the key checkpoints are (1) verbal patient consent documented in the chart per state AI-scribe laws (CA AB 3030 effective January 2025, TX SB 815 effective September 2025, UT HB 452, IL HB 1806 effective January 2026, NY S1331A pending), (2) physician review and signature before the note is finalized, and (3) no PHI sent to consumer-tier AI tools. The 2026 error-of-commission to avoid: signing a draft that miscoded a screening colonoscopy as a diagnostic (45378 vs 45380/45385) because the scribe heard 'polyp' but no resection was billed.
Can AI help with IBD biologic prior authorizations?
Yes — AI-assisted PA workflows (CoverMyMeds, Glidian, Myndshft, ePA integrated in Epic and athenaOne) cut PA-letter turnaround from 3-5 days to same-day for Humira, Stelara, Skyrizi, Rinvoq, Entyvio, Zeposia, Tremfya, Omvoh, and biosimilars. The AI drafts the medical-necessity letter citing ACG Crohn's and ulcerative-colitis clinical guidelines, failed conventional therapy (5-ASA + corticosteroid + immunomodulator), step-therapy documentation, and labs (CRP, fecal calprotectin, endoscopy). The physician reviews and signs — AKS and Stark still apply, and the letter must be truthful under the False Claims Act. For Medicare Advantage denials, the AI also drafts the plan-specific appeal citing the plan's own policy number.
Do FDA-cleared GI AI devices need ongoing validation?
Yes. Every CADe/CADx device on your tower is a Software-as-a-Medical-Device (SaMD) cleared under FDA 510(k) with stated indications-for-use. In 2026 the FDA's Predetermined Change Control Plan (PCCP) framework is active — vendors can update models within pre-authorized bounds, but your practice must maintain a quality log showing ADR/APC trends before and after each model version. If ADR drops, it is the practice's duty under 21 CFR 803 medical-device reporting to file a medical-device-report when device malfunction contributed to a significant adverse outcome. Keep the device-log alongside your endoscopy quality dashboard — GIQuIC and MIPS auditors ask for it.
What is the ROI for a 2-10 GI practice?
Three concentrated wins in 2026: (1) CADe screening — ADR goes up 8-14 percentage points in most real-world rollouts, translating to better MIPS composite scores and better payer contracts tied to quality; (2) ambient scribing — attending physicians recapture 45-90 minutes per clinic day, directly convertible into 2-4 additional procedure slots per week; (3) PA automation — one full-time prior-auth FTE now runs two-to-three physicians' biologic panels, and same-day PA turnaround reduces biologic-start drop-off by 15-25%. The practices that capture the margin are the ones that track CADe on-rate by endoscopist, scribe adoption by clinician, and PA turnaround weekly — not the ones that buy the most AI.
Sources & further reading
- HHS OCR HIPAA 45 CFR Parts 160, 162, 164
- FDA 510(k) SaMD Predetermined Change Control Plan (PCCP) 2024
- ACG Crohn's Disease Guideline 2018, Ulcerative Colitis Guideline 2019, IBS Guideline 2021
- AGA NAFLD/MASLD Practice Guidance 2023; AASLD; ASGE ERCP Quality Indicators
- USMSTF Post-Polypectomy Surveillance Guideline 2020; USPSTF CRC Screening 2021 (ages 45-75)
- CMS MIPS MVP Advancing GI Care 2025 + quality measure specifications
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465 + state medical-board advertising
- State AI-scribe + AI-use consent: CA AB 3030, TX SB 815, UT HB 452, IL HB 1806, NY S1331A